This inventor holds 3 USPTO granted patents. Top assignee: Pharnext. Active years: 2019-2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2019-2025
Title: Michael Sereda: Innovator in Charcot-Marie-Tooth Disease Treatment
Introduction
Michael Sereda is a notable inventor based in Göttingen, Germany. He has made significant contributions to the field of medical treatments, particularly focusing on Charcot-Marie-Tooth Disease (CMT). With a total of three patents to his name, Sereda is recognized for his innovative approaches to healthcare.
Latest Patents
Among his latest patents, Sereda has developed methods for the early treatment of Charcot-Marie-Tooth Disease type 1A (CMT1A). His invention involves administering a combination of baclofen, sorbitol, and naltrexone, or a pharmaceutically acceptable salt thereof, to subjects in need. This groundbreaking approach aims to treat, prevent, or delay the onset of this debilitating disease.
Career Highlights
Michael Sereda is currently associated with Pharnext, a company dedicated to developing innovative treatments for neurological diseases. His work at Pharnext has positioned him as a key player in the advancement of therapies for CMT and other related conditions.
Collaborations
Sereda collaborates with notable colleagues, including Daniel Cohen and Ilya Chumakov. Their combined expertise contributes to the ongoing research and development of effective treatments in the field.
Conclusion
Michael Sereda's contributions to the treatment of Charcot-Marie-Tooth Disease highlight his commitment to medical innovation. His patents and work at Pharnext reflect a dedication to improving the lives of those affected by this condition.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile